Although complement was originally described as a powerful defense mechanism against invading pathogens, it can also be activated by tumor-targeting antibodies to kill tumor cells. Antibody and Complement Activation Immunoglobulin (Ig) inductionRead More…
Complement factor B (CFB) inhibitors exert therapeutic effects by specifically binding to factor B, inhibiting abnormal activation of the complement bypass pathway, and controlling intravascular and extravascular hemolysis in paroxysmal sleep hemoglobinuriaRead More…
The complement system is an important component of innate immunity, playing a key role in defending against invading pathogens. It consists of approximately 60 soluble and membrane-bound proteins, including core components, receptors,Read More…
The immune complement system is a crucial component of the body’s intrinsic immunity, playing roles such as regulating immune responses and clearing pathogens. A growing body of research suggests that the complement system is aberrantlyRead More…
Microglia-neuron interactions regulate brain development, maturation, homeostasis, and disease genesis. The innate immune complement component C1q, produced and secreted by microglia, has brain function specificity. C1q acts as an initiating molecule forRead More…
The complement system is a primary barrier of the innate immune defense system formed by a series of proteins working in a highly coordinated manner to defend against microbial invasion of host tissues. InRead More…
The complement system, as an important component of the body’s immune system, plays a key role in tumor development and therapy. Tumor immunomodulation by the complement system has a dual role inRead More…
CD35, also known as complement receptor 1 (CR1), plays a crucial role in the complement system. The complement system is part of the immune system that recognizes and removes pathogens, promotes inflammatoryRead More…
Structure of Complement Regulatory Protein Factor H Complement Factor H, also known as Factor H and CFH, is a sialic acid-containing glycoprotein that plays an integral role in regulating the complement-mediated immuneRead More…
Dianthus Therapeutics’ (DNTH) primary asset is DNTH103, a selective monoclonal antibody targeting the active form of complement C1s. The main focus is a me-better version of Sanofi’s already-marketed C1s monoclonal antibody, Sutimlimab.Read More…